c19early.org COVID-19 treatment researchCOVID-19 treatments

Ramipril for COVID-19: real-time analysis

c19early.org
Ramipril for COVID-19
1 study with 114 patients
Serious outcome risk
Ramipril
Control
No significant improvements are seen in meta-analysis to date.
COVID-19 Ramipril studies · November 2026
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−144%
Mortality (1)−144%
RCTs (1)−144%
Late (1)−144%
00.511.5+
← Ramipril
reduces riskIncreased
risk →
Ramipril is an oral small molecule angiotensin-converting enzyme (ACE) inhibitor that blocks the renin-angiotensin-aldosterone system (RAAS).
Aug 24
2023
 Huang et al., Advances in Therapy, doi:10.1007/s12325-023-02618-7 Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
144% higher mortality (p=1), 289% higher ventilation (p=1), 289% higher ICU admission (p=1), and 144% lower hospital discharge (p=1). RCT 114 non-critically ill COVID-19 patients in the USA showing no significant differences with ramipril treatment.